Psoriasis: ixekizumab superior to FAEs, methotrexate in open-label trial

  • Reich K & al.
  • Br J Dermatol
  • 3 Aug 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Ixekizumab (Taltz) clearance rates are superior to those achieved with fumaric acid esters (FAEs) and methotrexate in patients with moderate to severe plaque psoriasis.

Why this matters

  • This is the first head-to-head trial comparing these commonly used therapies.

Key results

  • Ixekizumab was associated with a higher rate of ≥75% improvement in the Psoriasis Area and Severity Index (PASI-75; 90.7%) compared with methotrexate (70.4%; P=.0137) and FAEs (22.2%; P<.0001>
  • Ixekizumab was also associated with higher rates of PASI-90 (79.6% vs 38.9% for methotrexate [P<.0001 and for faes pasi-100 vs methotrexate>
  • 3.7% of patients treated with ixekizumab, 0% of patients treated with methotrexate, and 38.5% of patients treated with FAEs discontinued because of adverse events during the treatment period (P=.4954 for ixekizumab vs methotrexate; P<.0001 for ixekizumab vs methotrexate>

Study design

  • 162 patients with moderate to severe plaque psoriasis who had not previously received systemic treatment: 54 received ixekizumab, 54 were treated with FAEs, and 54 received methotrexate.
  • Funding: Eli Lilly.

Limitations

  • Relatively small sample size.
  • Open-label study design.